244 related articles for article (PubMed ID: 35839428)
1. Precision Medicine in Biliary Tract Cancer.
Scott AJ; Sharman R; Shroff RT
J Clin Oncol; 2022 Aug; 40(24):2716-2734. PubMed ID: 35839428
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
[TBL] [Abstract][Full Text] [Related]
3. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
4. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.
Mirallas O; López-Valbuena D; García-Illescas D; Fabregat-Franco C; Verdaguer H; Tabernero J; Macarulla T
ESMO Open; 2022 Jun; 7(3):100503. PubMed ID: 35696747
[TBL] [Abstract][Full Text] [Related]
5. Translating cancer genomics for precision oncology in biliary tract cancers.
Haber PK; Sia D
Discov Med; 2019; 28(155):255-265. PubMed ID: 32053766
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into molecular and immune subtypes of biliary tract cancers.
Bramel ER; Sia D
Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
[TBL] [Abstract][Full Text] [Related]
8. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
Zhu AX; Hezel AF
Hepatology; 2011 Feb; 53(2):695-704. PubMed ID: 21274890
[TBL] [Abstract][Full Text] [Related]
9. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
10. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.
Okamura R; Kurzrock R; Mallory RJ; Fanta PT; Burgoyne AM; Clary BM; Kato S; Sicklick JK
Int J Cancer; 2021 Feb; 148(3):702-712. PubMed ID: 32700810
[TBL] [Abstract][Full Text] [Related]
12. New Horizons for Precision Medicine in Biliary Tract Cancers.
Valle JW; Lamarca A; Goyal L; Barriuso J; Zhu AX
Cancer Discov; 2017 Sep; 7(9):943-962. PubMed ID: 28818953
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
14. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
15. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
16. Experimental HER2- targeted therapies for biliary tract cancer.
Rizzo A; Ricci AD; Bonucci C; Tober N; Palloni A; Frega G; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):389-399. PubMed ID: 33218269
[No Abstract] [Full Text] [Related]
17. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers.
Zhang R; Puzzoni M; Mariani S; Zheng Y; Liscia N; Guo Y; Donisi C; Liu Y; Impera V; Fang W; Scartozzi M
Cancer Sci; 2021 Dec; 112(12):4819-4833. PubMed ID: 34534382
[TBL] [Abstract][Full Text] [Related]
18. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
[TBL] [Abstract][Full Text] [Related]
19. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
20. Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
Marin JJG; Prete MG; Lamarca A; Tavolari S; Landa-Magdalena A; Brandi G; Segatto O; Vogel A; Macias RIR; Rodrigues PM; Casta A; Mertens J; Rodrigues CMP; Fernandez-Barrena MG; Da Silva Ruivo A; Marzioni M; Mentrasti G; Acedo P; Munoz-Garrido P; Cardinale V; Banales JM; Valle JW; Bridgewater J; Braconi C;
Br J Cancer; 2020 Sep; 123(7):1047-1059. PubMed ID: 32694694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
